-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
China's ophthalmic consumables industry started late and started from a low starting point.
In recent years, with the intensification of aging and the deepening of adolescent myopia, the number of ophthalmology clinics has continued to increase.
In 2019, the number of consultations has reached 127 million
.
As the incidence of ophthalmic diseases and the demand for diagnosis and treatment in China are increasing year by year, the access rate of ophthalmic surgery is also increasing, driving the continuous growth of the demand for ophthalmic consumables
.
At the same time, policies are also leaning toward the industry, adding assistance to the development of the domestic ophthalmic medical device industry, and the market scale is expected to continue to expand
.
Data shows that the domestic market for high-value medical consumables for ophthalmology has grown from 4.
7 billion yuan in 2015 to 7.
6 billion in 2018, with an average annual compound growth rate of 17.
4% from 2015 to 2018
.
It is understood that ophthalmic consumables require a high degree of refinement of technology.
In the past, domestic products were mainly concentrated in the low- and medium-value fields, and most of the high-value consumables depended on imports
.
In recent years, with the continuous efforts of domestic enterprises, listed companies with certain strengths such as Haohaishengke, Opcom, and Aibo Medical have emerged in the market
.
In terms of product categories, the high-value ophthalmology consumables market in China is dominated by intraocular lenses and orthokeratology lenses
.
Among them, the main advantage of intraocular lens is to improve the vision of the surgical eye in dim conditions and at night.
The industry is highly concentrated.
The domestic market is mainly occupied by Ibero-Tech and Haohaishengke.
The industry believes that the future competition of this product lies in new models.
In intraocular lenses, such as multifocal intraocular lenses, large depth-of-field intraocular lenses, adjustable intraocular lenses, etc.
; Orthokeratology lenses can slow down the effect of adolescents’ myopia progression.
As the myopia rate of children and adolescents in China continues to rise, the market for orthokeratology lenses It is also expected to grow, but the technical threshold of this product is relatively high.
Domestic brands mainly include Opcom, Ibernod and Taiwan Hengtai.
In addition, Haohaishengke’s wholly-owned subsidiary acquired 70% of the shares of Contamac in the UK to complete the transaction.
The layout of high-tech raw material suppliers in the upstream of the industrial chain
.
It is understood that in terms of volume, Opcom is in the position of a domestic industry giant
.
It is worth mentioning that high-value medical consumables have always had problems such as false high prices and overuse.
With the advancement of mass procurement, consumables medical devices have also become the target of centralized procurement.
In the future, the centralized procurement of consumables will also become normalized.
, The market growth rate may slow down to a certain extent, but it is conducive to the increase in the penetration rate of cost-effective domestic ophthalmic equipment, the market still has a large room for growth, and the competitiveness of domestic enterprises will also be significantly improved
.
In addition, medical devices are related to the health and life safety of the people
.
In recent years, with the rapid development of the medical device industry, the industry also urgently needs to be more standardized
.
In February of this year, China announced the new "Regulations on the Supervision and Administration of Medical Devices" (hereinafter referred to as the "Regulations"), requiring the implementation of the "four most stringent" requirements, and at the same time substantially increasing the fines and increasing penalties for industry and market bans
.
One of the highlights is the addition of the "punishment to the person".
The regulations are clear.
The legal representative, the main person in charge, the directly responsible person in charge and other responsible personnel of the unit with serious violations will be confiscated from the company during the period of the violation.
If they earn income, they can be fined up to 3 times, and they are prohibited from engaging in related activities for 5 years up to life
.
The regulations have come into effect on June 1, 2021
.
The industry believes that with the implementation of the regulations, it means that the medical device industry including ophthalmic consumables has entered a new stage of development, and the market has also ushered in a major reshuffle.
Under this background, some small and medium-sized enterprises may be eliminated , And process medical device companies with R&D capabilities, complete product layout, and standardized operations are expected to get a new round of opportunities
.
In recent years, with the intensification of aging and the deepening of adolescent myopia, the number of ophthalmology clinics has continued to increase.
In 2019, the number of consultations has reached 127 million
.
As the incidence of ophthalmic diseases and the demand for diagnosis and treatment in China are increasing year by year, the access rate of ophthalmic surgery is also increasing, driving the continuous growth of the demand for ophthalmic consumables
.
At the same time, policies are also leaning toward the industry, adding assistance to the development of the domestic ophthalmic medical device industry, and the market scale is expected to continue to expand
.
Data shows that the domestic market for high-value medical consumables for ophthalmology has grown from 4.
7 billion yuan in 2015 to 7.
6 billion in 2018, with an average annual compound growth rate of 17.
4% from 2015 to 2018
.
It is understood that ophthalmic consumables require a high degree of refinement of technology.
In the past, domestic products were mainly concentrated in the low- and medium-value fields, and most of the high-value consumables depended on imports
.
In recent years, with the continuous efforts of domestic enterprises, listed companies with certain strengths such as Haohaishengke, Opcom, and Aibo Medical have emerged in the market
.
In terms of product categories, the high-value ophthalmology consumables market in China is dominated by intraocular lenses and orthokeratology lenses
.
Among them, the main advantage of intraocular lens is to improve the vision of the surgical eye in dim conditions and at night.
The industry is highly concentrated.
The domestic market is mainly occupied by Ibero-Tech and Haohaishengke.
The industry believes that the future competition of this product lies in new models.
In intraocular lenses, such as multifocal intraocular lenses, large depth-of-field intraocular lenses, adjustable intraocular lenses, etc.
; Orthokeratology lenses can slow down the effect of adolescents’ myopia progression.
As the myopia rate of children and adolescents in China continues to rise, the market for orthokeratology lenses It is also expected to grow, but the technical threshold of this product is relatively high.
Domestic brands mainly include Opcom, Ibernod and Taiwan Hengtai.
In addition, Haohaishengke’s wholly-owned subsidiary acquired 70% of the shares of Contamac in the UK to complete the transaction.
The layout of high-tech raw material suppliers in the upstream of the industrial chain
.
It is understood that in terms of volume, Opcom is in the position of a domestic industry giant
.
It is worth mentioning that high-value medical consumables have always had problems such as false high prices and overuse.
With the advancement of mass procurement, consumables medical devices have also become the target of centralized procurement.
In the future, the centralized procurement of consumables will also become normalized.
, The market growth rate may slow down to a certain extent, but it is conducive to the increase in the penetration rate of cost-effective domestic ophthalmic equipment, the market still has a large room for growth, and the competitiveness of domestic enterprises will also be significantly improved
.
In addition, medical devices are related to the health and life safety of the people
.
In recent years, with the rapid development of the medical device industry, the industry also urgently needs to be more standardized
.
In February of this year, China announced the new "Regulations on the Supervision and Administration of Medical Devices" (hereinafter referred to as the "Regulations"), requiring the implementation of the "four most stringent" requirements, and at the same time substantially increasing the fines and increasing penalties for industry and market bans
.
One of the highlights is the addition of the "punishment to the person".
The regulations are clear.
The legal representative, the main person in charge, the directly responsible person in charge and other responsible personnel of the unit with serious violations will be confiscated from the company during the period of the violation.
If they earn income, they can be fined up to 3 times, and they are prohibited from engaging in related activities for 5 years up to life
.
The regulations have come into effect on June 1, 2021
.
The industry believes that with the implementation of the regulations, it means that the medical device industry including ophthalmic consumables has entered a new stage of development, and the market has also ushered in a major reshuffle.
Under this background, some small and medium-sized enterprises may be eliminated , And process medical device companies with R&D capabilities, complete product layout, and standardized operations are expected to get a new round of opportunities
.
